Herpes zoster - Iherpes Zoster
☆ AI Dermatology — Free Service
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Herpes zoster ibangela amadyuzang entanyeni nasegxalabeni.
relevance score : -100.0%
ReferencesIshingles, ezibangelwa ukuvuselelwa kwentsholongwane ye‑varicella zoster ebangelwa nenkukhu, ichaphazela malunga ne‑1 yezigidi zabantu ngonyaka e‑United States, kunye nomngcipheko wokufa oyi‑30 %. Abantu abanemozulu omzimba obuthathaka baqheleke kakhulu ekuphuhliseni i‑shingles, kwaye iimpawu zokuqala zibandakanya i‑malaise, intloko ebuhlungu, kunye nomkhuhlane ongapheliyo, okulandelwa kukuziva okungaqhelekanga kwesikhumba kwiintsuku ezimbalwa ngaphambi kokuvela kwerash. Olu rash luqala kwindawo ethile emzimbeni, luqhubela phambili ukusuka kumadyunguza acacileyo ukuya kwizilonda ezirhabaxa ngaphezulu kweveki, lize lize lube yizilonda ezinzima ukuya kwiintsuku ezilishumi. Unyango olukhawulezayo ngamayeza e‑antiviral (acyclovir, valacyclovir, okanye famciclovir) phakathi kweeyure ezingama‑72 emva kokuqhuba i‑rash kubalulekile. I‑postherpetic neuralgia, ingxaki eqhelekileyo ebonakaliswe yintlungu ehlala ixesha elide kwindawo echaphazelekayo, ichaphazela malunga nesinye kwizigulane ezihlanu, kwaye ifuna ukulawulwa okuqhubekayo ngeeza ezifana ne‑gabapentin, i‑pregabalin, okanye i‑antidepressants ethile, kunye ne‑topical agents ezifana ne‑lidocaine okanye i‑capsaicin. Ugonyo oluchasene nentsholongwane ye‑varicella zoster luyacetyiswa kubantu abadala abaneminyaka engama‑50 nangaphezulu ukunciphisa ingozi ye‑shingles.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Herpes zoster idla ngokwenzeka rhoqo kubantu abaneminyaka engama-50 nangaphezulu, abanemijoni yomzimba ebuthathaka, kunye nabathatha amayeza e‑immunosuppressant. Ibangelwa kukuvuselelwa kwentsholongwane ye‑varicella‑zoster, intsholongwane efanayo eyenza inkukhu. Iimpawu ezinjengomkhuhlane, iintlungu, kunye nokurhawuzela zikholisa ukuba phambi kokubonakala kwerhashalala. Eyona ngxaki ixhaphakileyo yi‑post‑herpetic neuralgia, eyona ntlungu yemithambo ye‑nerve eqhubekayo emva kokuba irhashalala iphele. Izinto ezinobungozi kunye neengxaki ezinxulumene ne‑herpes zoster ziyahluka ngokuxhomekeke kwiminyaka, impilo ye‑immune, kunye nexesha lokuqalisa unyango. Ukugonywa kwabantu abaneminyaka engama‑60 nangaphezulu kubonakaliswe ukunciphisa kakhulu ukwenzeka kwe‑herpes zoster kunye ne‑post‑herpetic neuralgia. Ukusetyenziswa kokuqala kwamayeza e‑antiviral kunye neentlungu zokuthomalalisa kwiiyure ezingama‑72 zokuqhuba kwerhashalala kunokunciphisa ubunzima kunye neengxaki ze‑herpes zoster kunye ne‑post‑herpetic neuralgia.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Ulingo lwezonyango phambi kolwamkelo lubonisa ukuba isitofu sokugonya esiphilayo sisebenza malunga ne-50 % ukuya kwi-70 %, ngelixa isitofu sokugonya esiphinda siphinde sisebenza ngcono, ukusuka kwi-90 % ukuya kwi-97 %. Kuphononongo lwehlabathi lokwenyani, iziphumo zixhasa le miphumo, ezibonisa ukuba isitofu sokugonya esiphilayo sinokusebenza malunga ne-46 % ngelixa i-recombinant inokusebenza malunga ne-85 %.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
I‑Chickenpox, ekwabizwa ngokuba yi‑varicella, isiphumo sosulelo lokuqala lwentsholongwane, oluhlala lusenzeka ebuntwaneni okanye ebusheni. Nje ukuba inkukhu iphole, i‑varicella inokuhlala ingasebenzi (ilele) kwiiseli zemithambo‑luvo yomntu iminyaka okanye amashumi eminyaka, emva koko inokuphinda isebenze. I‑herpes zoster (herpes zoster) yenzeka xa i‑varicella ephumileyo iphinde isebenza. Le ntsholongwane ihamba kwimithambo‑luvo iye kwincam yemithambo‑luvo eluswini, ivelisa amadyungudyungu. Ngexesha lokuqhambuka kwe‑herpes zoster (herpes zoster), ukuvezwa kwintsholongwane ye‑varicella efumaneka kwi‑herpes zoster (herpes zoster) kunokubangela irhashalala kumntu ongakabi nalo irhashalala.
Imiba esemngciphekweni yokuphinda isebenze intsholongwane ephumileyo ibandakanya ukwaluphala, ukungakhuseli kakuhle komzimba, kunye nokuba wosulelwe irhashalala ngaphambi kweminyaka eli‑18 ubudala. Intsholongwane ye‑Varicella zoster ayifani nentsholongwane ye‑herpes simplex, nangona bobabini bentsapho enye ye‑herpesviruses.
I‑herpes zoster (herpes zoster) i‑vaccine ye‑izitofu zokugonya yehlisa umngcipheko we‑herpes zoster (herpes zoster) ngo‑50 % ukuya ku‑90 %. Kwakhona yehlisa amazinga e‑postherpetic neuralgia, kwaye, xa i‑herpes zoster (herpes zoster) yenzeka, ubunzima bayo. Ukuba i‑herpes zoster (herpes zoster) ivele, amayeza e‑antiviral afana ne‑aciclovir anokunciphisa ubukhali kunye nobude besifo ukuba aqaliswe ngaphakathi kweeyure ezingama‑72 emva kokuqalisa irhashalala.
○ Unyango
Ukuba izilonda zisakhula ngokukhawuleza, qhagamshelana nogqirha wakho ngokukhawuleza ukuze ufumane unyango lwe‑antiviral.
Kufuneka kusetyenziswe amayeza e‑antiviral kunye ne‑neuralgia. Kufuneka uphumle uyeke ukusela utywala.
#Acyclovir
#Fancyclovir
#Valacyclovir
#Gabapentin
#Pregabalin